HUE031972T2 - Diamin-származékok mint leukotrién A4 hidroláz inhibitorok - Google Patents
Diamin-származékok mint leukotrién A4 hidroláz inhibitorok Download PDFInfo
- Publication number
- HUE031972T2 HUE031972T2 HUE06848156A HUE06848156A HUE031972T2 HU E031972 T2 HUE031972 T2 HU E031972T2 HU E06848156 A HUE06848156 A HU E06848156A HU E06848156 A HUE06848156 A HU E06848156A HU E031972 T2 HUE031972 T2 HU E031972T2
- Authority
- HU
- Hungary
- Prior art keywords
- methyl
- phenyl
- compound
- formula
- nmr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
- OIÄMiN-SZÄRMMEKGK MINT LEUKOTRIEN A4 HIDROLÂZ INHIBITOROK SZABADALMI IGÉNYPONTOKkepletu vegyidet, amelyben az R jelentőseamelyben r értéke 0-4, R'3, Ru\ R1e, R1d és R1e jelentése egymástól függetlenül hidrogénatom, ~R’3~OR10, *R13«C(«0)OR10, ^'á«0(«O}R10, álkslesoport, halogénafem, hafogén-áíkih cíano, cíkioaikih dklöátkíí-atkik aril-, araiklk heieroahk heteroarií-alkik heterodklll" vagy ΙιοίθΓΟοΙΚΙΙΡοΙ^ΙΡοδοροΓΐ; Rj egy közvetlen kötés, -0-, -R,2-ö-, -Ö-R1·"·-, -O-R^-O- csoport, egy egyenes vagy elágazó alkiféndáno, egy egyenes vagy elágazó alkeniiéndánc vagy egy egyenes vagy elágazó aikiniién-iánc; R4 egy közvetlen kötés, ~Ö-Rn';k egy egyenes vagy elágazó aíkilén-lánc, egy egyenes vagy elágazó alkenílén-láne vagy egy egyenes vagy elágazó alkímián-lánc; R8 jelentése aralkil-csoport, amely adott esetben egy vagy több, a halogénatom, nitro-, ölano-, heteroaril-, hidroxi-lmino-aikik ~R'3~ORs0, ~R1S-G(~Ö)R10, -R13-C(“0}0R1ös ~R13~C(-O}-R13-N(R10)R11,~R,3'-C{“O)N{R10)~R14-N(R10)R11, -R13-8{=O)tN(R10}R11 (ahol t értéke 1 vagy 2), -R13-N(R10)R11, -R'3-N(R10)C{^O)R1g, ~R13-N(R10}a(«O)-Í13~N{R1ö)R-1, · R13" H (R10}-R13-C( ~0)QR * G, -R13-N(R10}C(~O)-R14~S{«O}«N{R1ö}R11 fáhdS f értéke 1 vagy % ~R13~N(R1ö)C(s:;ö)~Rt3''N{R10}C(“O)R1'5i ~R13"N(R10}C(“Ö)”R13'-N(Rlö}“Rv’“N(R1®)R11, »R:iä-N|Riö)Sf^öp{R10}R11 (ahoi t értéte 1 vagy 2) és ~R13-G-R14~C(<))ÔR10 csoport Illái alkotott csoportból kiválasztott csoporttol von szubszíituálva; minden R9 jelentése egymástól függetlenül -O-R10, alkíh hidroxí-alkil-csoporl halogénatom, halogén-alkil·, aril· vagy aralkil-csoport; minden Rí0 és Rri jelentése egymástól függetlenül hidrogénatom, aikli-, halogén-aíksk hidroxl-alkil-, aril··, aralklî-, hetaroanh, heferoaril-alkík haterociklfi- vagy héteroolklil-alkikosópoft; vagy R10 és f?\ együtt azzal a nitrogénnel, amihez kapcsolódnak, egy N~ heierodkiii- vagy egy A/~heteroari!~csoportöt képeznek; R1S egy egyenes vagy elágazó alkilén-lánc, egy egyenes vagy elágazó alkenllén-lánc vagy egy egyenes vagy elágazó alkinilén-lánc; R10a egy egyenes vagy elágazó alkilén-lánc, egy egyenes vagy elágazó aíkenilén-lánc vagy egy egyenes vagy elágazó alkinilén-lánc; és minden R13 jelentése egymástól függetlenül közvetlen kötés, egy egyenes vagy élágazó alkilén-lánc, egy egyenes vagy elágazó aíkenilén-lánc vagy egy egyenes vagy éiágazó álkíniíihdánc; vagy ennek gyógyszerészetsleg elfogad hité sója, szolvátja, polimorfja, klatrátja, ammóniumionja vagy /V-oxidja
- 2. ÁZ 1, jglnyponf szerinti vegyilet ámelybep R3 egy közvetlen kötés, -O-, -Ö-R12-, ~0~R1:?-ö- csoport vagy egy egyenes vagy elágazó alküén-lánc; R4 egy közvetlen kötés, OR12a- csoport vagy egy egyenes vagy elágazó aíkilén-lánc: R8 jelentése aralkil-csoport egy vagy több, az-R13-GR1í), -R13~C(~Q)QR!° és az *R^dC^“Ô;)N.(R-®)R11 által alkotott csoportból kiválasztott csoporttal van szubszíituálva; minden R9 jéléntése függetlenül alkilcsoport, halogénatom vagy -Û-R10 csoport; R1:‘ ogy egyenes vagy elágazó alkilén-lánc; R m ©ipnes vagy elágazó alkilén-lánc; és minden R13 jelentés©· közvetlen kötés vagy egy egyenes vagy elágazó aíkiiémlánc, amelyben előnyösen: r értéke 0; R3 jelentése közvetlen kötés, -ö-,. -R12*0«, ->OR!2h -Ö-Rv'"~tb csoport vagy egy ajkilén-lánc; R4 jelentése közvetlen kötés, -Ö-R:12a~, vagy egy egyenes vagy elágazó alkilen-láne; R8 jelentése benzil-csoport, egy vagy több, az ~R13-OR10 és az ~R13-C(~Ö)ÖR10 által alkotott csoportból kiválasztott csoporttal szubsztituálva; Rí0 jelentése hidrogénatom, alkil- vagy arilcsoport; R12 jelentése 1-6 szénaíomos alkslén-csoport; és R123 jelentése maillén- vagy etilén-csoport. 3. A 2. igénypont szerinti vegyület, amelyben r értéke ö; R3 jelentésé közvetlen kötés, -Ö-, -R12-CK O-R12*, -Ö-R12-Ö-- csoport vagy egy alkllén-iáno; R4 jelentése közvetlen kötés, ~Ú~R12% vagy egy egyenes vagy elágazó alkllén-iáno; R8 jelentése benzil-csoport, egy vagy több, az -R^-ÖR10 és az ~R13-C(~0)0RK·' által alkotott csoportból kiválasztott csoporttal szubsztituálva; R!° jelentése hidrogénatom, alkil- vagy árucsoport; R12 jelentése 1-6 szénatomos alkiíén-csoport; és R12a jelentése mattién- vagy etilén-csoport.
- 4. Az előző igénypontok bármelyike szerinti vegyület amelyben R3 jelentése ~0~ csoport.
- 6. Az előző igénypontok bármelyike szerinti vegyület, amelyben R4 egy egyenes vagy elágazó alkilén-lanc6. Az előző igénypontok bármelyike szerinti vegyület, amelyben R:^ jaiÉnîése bidro§inatOf?i, “R13“C(~0)QRu\ *R13->GpO)R10, alkiîcsoport, hai®*· gênaîom, plano“, cíkloaikih cikloaikibalksk aril··, araikik heieroSfik beíefoankaiklh betamiófkiík vagy beteMelktkaikíl-csopori; és R:b, R1c, R1ci és R10 imíi^sN^ylKe' vagy halogénafom, ?, A Elgényponí szerinti vegyüíei, amelyben R1s félédíésé hidrogénatom, -R13~C(-Ö)GR10, ~R13~C(~G)R1!* Síkiicsopöfb haio-génaíobb balpgén-alkil·, fenil-, furanil·, tienik tiazoiil- vagy oxazoiihcsoport; és R1b, R1c, R1cí és R!e m i nd a g ÿ î ka h id ?o g é n a to m. 8. 1 > igénypaní Slifííptí vagyúiet, aho! a vegyületet a 4~[{(1 SkSj-S-IS^d^fenil-metii'i-fenoxketiil'-Sk-diazabidkfok^.l jhept'2~il}-metiil'· -benzoesav; 4-(((1 S !4Sy5"|'{4'fenoxi"fenii)--mefil}-2,5-diazabicsk!o|'2,2.1]hept-2“i!]-meiilk -benzoesav; 4~[{{ 18í4S}-'5''{[4-(4-fSuor-'fenöxi>fenll]-métH}-2>6~díazabícikio[2.2,1 ]hept"2~ii)-metiik ‘benzoesav; 4''[({1S!4S)-5-{[4~(2~feníi-eiOoXi}-fön!l]-mefil)-2,5-díazabscik!o[2,2.1]hept“2'-í!)~metii]'- «benzoesav; 4-({(1 Í,4S)-iip^P”fenöxi“fen!l)«pPipíj|«2,S"diazabieskíp{2.2.1 jhept~2~ií}-metíl^ •benzoesav; 4~[({1S!4S)-'5-'{[4j{4"kíór--fenc)xi}-fenii]“met!Ík2!5'díazablcikioí2k.1 (hept~2~Sl}~meí$k “benzoesav; 4-(|(1 SpS}"lN|2-{4--fenoxi«fenÍíketÍik2p»diazabicík!oÍ2,2;í|bopb2-i|-matiÍ)~ -benzoesav; 4-[((1Si4S}-5-{{4-(2-fenoxi-eto;<s}-fenil]-nietií}~2,5~diazabiciklo[2,2.1]hept-2-!Í)'metíl]« -benzoesav; 4-{((1S,4S}~5“{[4~(4“bróm~fonoxíHeníl]~meíil}"2i5-diazabiciklo[2,2,1|hopt--2“Hk -meíiíj-benzoesav; 4~{[{1 S/iSl-S-P-fk-^-kiór-feniiVmetiO-fénoxiketiíhSk-diazabícikbpk.llhepna-ÍS]-“metil}-benzoesav; 4“{[(1Sí4S|-8-(2~{4“[(44luor“fení!)“metí!]-fenoxíke!ii)~2J-diazabídÉíoi2,2.1]hep|“2‘- 4i]-metil}~benzoesav; 4~{[{1 S,4S)"5“({4~[{2'“fíuoro[1,1 ’~bífeni!3~44l}-öxO-feríí|“meti!)~ÍJ-»d!azabicikio[2,2.1jhept-2~ii]-metii}-henxoesav; 4-{[{1S)4S)-5~({4"|4~{34uranyHenoxr|4'eni!}-rriefí!}--2,5'^i^2:abidkló|2.2.1]h€ípt-'2--íi]- -niitt^biOZoesav; 4“[{{1S,4S)~5-'({4'-[4-{írifluor~metilHenox!Henii}~metil}"2j5~c!iazabicíkloí2.2.1]hept''2“ *i$*rneti!J-benzoesav; 4~[((1S,4S)~5--{[4~(4“acetí!~fenoxi)--fení!]~met|l}~2i5"diazabicikÍD[2.2.1|hepí"':2"^}'' »metin-benzoésáv;2-Hr -mei!|~benzoessv; 4-([(1S!4S)~5~({4-[4-(3)5~climeti!--4~!zoxazo!ll)~fenoxíj"fensl}''met]i)"2>5" -diazabteíklopL2.1 ]hept~2-iS]-meti!}-benzoesav; ^ ϊΤ!βί#' 4--(((1 S>4S)->S~{(3“flüor-'4~fenoxi4eníl}~maílO''2*S“dlazabicík!o[2.2.1]h©pir^ í j -b®«ö*sa»; eiötií· 4'[fi13,43)'5-{[3-{2~ί0ηί1-βΐοχί}-ίθηί!]-ιη0ίίΙ}'2,5-ίίί8Ζ36ιοιί\!ο[2,2.1]Ι'!βΡί'^ ! -henzoesav; 4-ff(1 S14S)“5--({4^(4-(2^xazDlil)-fenpxí]-'fanl|-matiÍ5^2J^dlazal3iail<íd['i'·'*· -metij}~benzoesav; ^{V 44.{(1S,4SV5-'[(44íuor-2463noxi“fenil)-metíif2;6''diazabicik!o[2,2..1}bePt"'''< -henzoesav; smmmm ^ π.^ΐ)' 4-(((18!4δ)~δ~((2·-ΐ1υθΓ~4~ίΘηοχΐ4βη!!)·-Γηβ!!ΐ]~2,5-άίΒΖβ0ίο1Ι<ίο|2.2.1]ΗβΡ^' * -benzoesav; A.,v 4-((( 1S ,48 )-5-4(2J4'-däfenoxi“ienil)-'metH|--2,5-dlazabidkSo[2-2,1]hept''2-'ii-' -béniééliV; 4-((18,43)-5-(((1 )1'-bsfeni1'-44l}-'meiil]-'2s5~diazabidklo[2.2J}hfôpt-'24!}'-rïie 1 -benzeesav; -benzolecetsav; ^4·#*#*®' “benzoiecetsav; 4-(((1 Sl4S}~6-{[4~(24eni!-etoxi}-fenil]~metil}'-215'-dlazabicikio[2.2l 1 ]heP*"A * -benzoiecetsav; rnetii~4~[(1S,4S)~5~({4"f4~(2~oxazolií)4enöxlJ''feníi)“metíÍ}-2>5--diazâbiôikSô[2.2.1 jhept-2-il]-metiihenzoát; 4-{[( 1S ,4S)-5-({4~[4-{2-ti8ZöiltHeoozi|-Ä 1 ]hept“2~i1j- -metííl-benzoesav; és a 0^4(1-4-(1(1 S!4S}“5~({4-í4~(24iazollí)~fenoxö~feni!rmetíl)“2,5“díazabjdk!o[2<2.Tjhapt“ *2it*meti|-benzöát ital alkotott csoportból választjuk ki. 9. Ä 8, igénypont szerinti vegyület ahol a vegyületet a 4ΗΙ(.1:β,43}-5-{(4-|4--(2-oxazolil}“fenox!]~fenil}-metii)~2í5-diezabic!klo[2,2.1}hept-2-il}-mati!}~benzoesav.
- 10. Gyógyszerkészítmény, amely tartalmaz egy gyégyszerészelíeg elfogadható kötőanyagot valamint tartalmiba egy, az előző igénypontok bármelyike Wb rínti vegyület terápiásán hatásos mennyiségét.
- 11. Gyógyszerkészítmény, amely tartalmaz egy gyógyszerészetileg elfogadható kötőanyagot valamint a 9, igénypont szerinti vegyületet 12. A10-11. igénypontok bármelyike szerinti gyógyszerkészítmény, ahol a készítmény egy helyi készítmény,
- 13. Az 1-9. igénypontok bármelyike szerinti vegyület vagy a 1Ö-12. igénypontok bármelyike szerinti gyógyszerkészítmény terápiában való alkalmazásra.
- 14. Az l -iyígénypontok iármelpke szerint vegyület, az LIArh aktivitásnak egy emlősben vaíó gátlásával enyhített betegség vagy rendellenesség kezelésében váló áikiímazásra.
- 16. Vegyület á 14, igénypont szerinti alkalmazásra, ahol a vegyület a 4- ~[{{ 1 S,4S)"5-'({4“l4-'(2“Oxa2olil)~fenöxí]-feníi}-met(i)-2,5-€liazabiclkiol2.2.1 Jhept-2~il}~ metiij-benzoesav.10. Vegyület a 14. vagy 15, igénypont szerinti alkalmazásra, ahol a betegséget vagy rendellenességet az iyul^îls, krónikus gyulladás» anafilaxiás reakciók» .allergiás reakciók, allergiás kontakt dermatitis, allergiás rhinitis, kémiai és nem-specifikus irritáló kontakt déóóatítis, csalánkiütés, atópiás dermatitis, psoriasis, Crohn-betegséggeI asazoeiilt lannyedés, pouchitis, szeptikus vagy endotoxikus sokk, vérzéses sokk, sokkszerű szindrómák, rák immunterápiája áitaí indukált kapilláris rés szindrómák, akut légzési fájdalom szindrörna, szkieroderroa tüdőbetegség, traumás sokk, lmniun~ is patogén-indukált tudögyuilrtóások, immun-eompiex-kozvetiteit tüdökárcsodás és krónikus obstruktiv tüdőbetegség, gyulladásos bélhetegségek, uioetetív köilisz, Crohn-betegség, műtét utáni trauma, gasztrointesztinälis fekély, ísémiás-reperfuziós károsodással asszociált betegségek, akut szívizom isémia, infarktus, akut vesekárosodás, isémiás bélbetegség, akut vérzéses vagy isémiás stroke, immune-oornpiex^kőzveílett glomerulonephritis, autoimmun betegségek, inzulin-'dependens diabetes melius, sclerosis multiplex, rfieumatcid arthritis, osteoarthritis, szisztémás lupus eífteematosus, akut és krónikus szerv-transzpfantáium Miikődéi, transplant arteriosclerosis, transplant fibrosis, szív-érrendszeri rendellenességek, Npertenzió, atherosclerosis, aneurizma, kritikus láb Isémia, perifériás. artériás elzáródásos betegség, Reynaucl-szindróma, diabetikus nefrepátfa, neuropátia, refinopátia, macula degeneráció, glaucoma, neurodegenerátiv rendellenességek, késiekéiért neurodegeneráeiő a stroke-ban, Afzhéimenkér, Parklnsómkór, encephalitis, HIV demeneía, gyulladásos fájdalom, neuropátiás fájdalom, arthritiszes fájdalom, pertodontalis betegség, gingivitis, fülgyuliadások, migrén, benign prostatic hyperplasia, rák, leukémiák, limfómák, prosztata rák, mellrák, tüdőrák, nialígnáns melanoma, vese carcinoma, feltúrnotok, nyaktumorok és vastag- és végbél-rák által alkotott csoportból választjuk ki. 17, A 16, igénypont szennfi áikálrnázisra szeigiió vegyuiét, ahoi a gyulladó-sós bélbetegséget az uiceratív coíitis, a Crohn-betegség és a műtét utáni trauma liai átkötött csoportból választjuk ki.
- 18, Á l l, igénypont szenntl alkaimazism szolgáló vegyűíei ahol az autoim-mun betegséget az inzulntelepindens dlábétes méilitus, sole rheumatoid árthnis , osteearthris és a szisztémás lupus erythematosus által alkotott csoportból választjuk ki. 19. A 18, igénypont szerinti alkalmazásra szolgáló vegyület, ahoi a szív-érrendszeri rendellenességet a hípertenzio, atherosclerosis, aneurizma, kritikus íáb isémía, perifériás artériás elzáródásos betegség és a Reynaud-szindréme ália! á!kötött ésppödlő! választjuk ki. 20. A 16. igénypont szerinti alkalmazásra szolgáló vegyüiet, ahol a neurödegeneratfvrendeflenességel a késleltetett neurodegeneráció a stroke-ban, az AizhoimenMr, Parkinson-kón encephalitis és a HÍV demeneia által alkotott csoportbői választjuk ki.
- 21. Vegyüiét a 14. vagy 15. Igénypont szerinti alkalmazásra, ahoía betegséget vagy rendellenességet az asztma, krónikus bronchitis, bronchiolitis, bronchiolitis obliterans, a légzőszerv allergiás gyulladása, eozínofil granuloma, tüdőgyulladások, puímonárís fibrózisok, kötőszövet! betegségek pulmonáris megnyilvánulásai, akti és krónikus tttdokárosodás, krónikus obsíruMív tüdőbetogsé-gakpléfneît légzőszerv! károsodás szindróma és a tüdőnek mis, eozinofii infilírád-oval jellemzett, nem-fertőző gyulladásos rendellenességei által alkotott csoportból választjuk ki. 22. A 1 őt igénypont szerinti alkalmazásra szóig álé vegyüiet, ahol a rákot a leukémia, Hmfóma, prosztata-rák, mellrák, tüdőrák, maiignáns melanoma, vese karcinóma, fej- és nyak-tumorok és a vastag-· és végbél-rák által alkotott csoportból választjuk ki
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75542105P | 2005-12-29 | 2005-12-29 | |
US83581906P | 2006-08-04 | 2006-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE031972T2 true HUE031972T2 (hu) | 2017-08-28 |
Family
ID=38080959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE06848156A HUE031972T2 (hu) | 2005-12-29 | 2006-12-22 | Diamin-származékok mint leukotrién A4 hidroláz inhibitorok |
Country Status (15)
Country | Link |
---|---|
US (8) | US7737145B2 (hu) |
EP (2) | EP3205644A1 (hu) |
AR (1) | AR058404A1 (hu) |
CY (1) | CY1118837T1 (hu) |
DK (1) | DK1976828T3 (hu) |
ES (1) | ES2614090T3 (hu) |
HU (1) | HUE031972T2 (hu) |
LT (1) | LT1976828T (hu) |
PE (1) | PE20071176A1 (hu) |
PL (1) | PL1976828T3 (hu) |
PT (1) | PT1976828T (hu) |
SI (1) | SI1976828T1 (hu) |
TW (1) | TW200730474A (hu) |
UY (1) | UY30070A1 (hu) |
WO (1) | WO2007079078A1 (hu) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1976828T3 (en) * | 2005-12-29 | 2017-03-06 | Celtaxsys Inc | DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE |
JP2011500727A (ja) * | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
TW200932236A (en) * | 2007-10-31 | 2009-08-01 | Janssen Pharmaceutica Nv | Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase |
EP2257524B1 (en) | 2008-02-01 | 2016-01-06 | Brickell Biotech, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
JP2011512359A (ja) * | 2008-02-14 | 2011-04-21 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物 |
JP2011513242A (ja) * | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体アンタゴニスト |
US8426449B2 (en) * | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
TWI386204B (zh) | 2008-04-10 | 2013-02-21 | Mitsubishi Tanabe Pharma Corp | 高半胱胺酸合成酶抑制劑 |
MX2010011154A (es) | 2008-04-11 | 2010-12-21 | Janssen Pharmaceutica Nv | Tiazolopiridin-2-iloxi-fenilo y tiazolopirazin-2-iloxifenilaminas como moduladores de la leucotrieno a4 hidrolasa. |
CN102076661B (zh) * | 2008-07-03 | 2014-04-09 | 潘米拉制药公司 | 前列腺素d2受体的拮抗剂 |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
US20100173313A1 (en) * | 2009-01-08 | 2010-07-08 | Amira Pharmaceuticals, Inc. | Biomarkers of inflammation |
WO2010132599A1 (en) | 2009-05-14 | 2010-11-18 | Janssen Pharmaceutica Nv | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
CA2768587A1 (en) * | 2009-08-05 | 2011-02-10 | Panmira Pharmaceuticals, Llc | Dp2 antagonist and uses thereof |
AU2011203649A1 (en) | 2010-01-06 | 2012-06-14 | Brickell Biotech, Inc. | DP2 antagonist and uses thereof |
BR112014000087B1 (pt) * | 2011-07-04 | 2021-08-17 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas do receptor ep4 |
CA2905340C (en) * | 2013-03-12 | 2022-05-31 | Celtaxsys, Inc. | Low dose oral formulations of acebilustat |
AU2014240042C1 (en) * | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
WO2014152536A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
WO2014152518A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
WO2015006691A1 (en) * | 2013-07-11 | 2015-01-15 | Evestra, Inc. | Pro-drug forming compounds |
CN105530923B (zh) | 2013-09-09 | 2019-07-23 | 佩洛通治疗公司 | 芳基醚及其用途 |
ES2737148T3 (es) | 2013-12-16 | 2020-01-10 | Peloton Therapeutics Inc | Análogos de sulfona y sulfoximina cíclicos y usos de los mismos |
EP3267792A4 (en) | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
US10464896B2 (en) * | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
FR3038605B1 (fr) * | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation |
JP7011830B2 (ja) | 2015-10-14 | 2022-01-27 | エックス-サーマ インコーポレイテッド | 氷晶形成を低減するための組成物および方法 |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
AU2017371353B2 (en) | 2016-12-09 | 2022-02-03 | Celltaxis, Llc | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase |
WO2018107167A1 (en) | 2016-12-09 | 2018-06-14 | Celtaxsys, Inc. | Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase |
AU2017371348B2 (en) * | 2016-12-09 | 2022-02-03 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2019222265A1 (en) * | 2018-05-15 | 2019-11-21 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
EP3801559A4 (en) | 2018-05-31 | 2022-03-02 | Celltaxis, LLC | METHOD FOR REDUCING LUNG EXACERBATIONS IN PATIENTS SUFFERING FROM RESPIRATORY DISEASE |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
PE20211543A1 (es) * | 2018-10-18 | 2021-08-16 | Essa Pharma Inc | Moduladores del receptor de androgenos y metodos para su uso |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
AU2021255723A1 (en) | 2020-04-17 | 2022-12-08 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6130554A (ja) | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
DE3608088C2 (de) | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
IL87116A (en) | 1987-07-17 | 1993-03-15 | Schering Ag | 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same |
US5308852A (en) | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
WO1997029774A1 (en) * | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
JP4044967B2 (ja) | 1997-02-10 | 2008-02-06 | 小野薬品工業株式会社 | 11,15−o−ジアルキルプロスタグランジンe誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
US6309561B1 (en) | 1997-12-24 | 2001-10-30 | 3M Innovative Properties Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
EP1042283B1 (en) | 1997-12-25 | 2004-02-25 | Ono Pharmaceutical Co., Ltd. | Omega-cycloalkyl-prostaglandin e2 derivatives |
US6380203B1 (en) | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
JP4087938B2 (ja) | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
JP2001354657A (ja) * | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
DE60114518T2 (de) | 2000-07-06 | 2006-08-10 | Fuji Photo Film Co. Ltd., Minamiashigara | Flüssigkristallzusammensetzung, die Flüssigkristallmoleküle und Ausrichtungsmittel enthält |
JP4365094B2 (ja) * | 2001-03-02 | 2009-11-18 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害薬 |
AUPR362001A0 (en) * | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
CA2460313C (en) | 2001-09-14 | 2011-03-08 | Tularik Inc. | Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
CA2502357A1 (en) | 2002-10-17 | 2004-04-29 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction; methods of treatment |
EP1562973A4 (en) | 2002-10-17 | 2007-01-03 | Decode Genetics Ehf | RECOMMENDATIONS FOR MYOKARDINFARKT |
WO2005075022A2 (en) | 2004-01-30 | 2005-08-18 | Decode Genetics Ehf. | Susceptibility gene for myocardial infraction, stroke, and paod; methods of treatment |
US7851486B2 (en) * | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
US20040198777A1 (en) | 2002-12-20 | 2004-10-07 | Mitokor, Inc. | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto |
JPWO2004089410A1 (ja) | 2003-04-03 | 2006-07-06 | 協和醗酵工業株式会社 | 神経因性疼痛の予防及び/または治療剤 |
WO2004099164A1 (en) * | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
AU2004261628B2 (en) * | 2003-07-28 | 2011-05-12 | Janssen Pharmaceutica N.V. | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators |
US20050272051A1 (en) | 2003-09-17 | 2005-12-08 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
ATE437880T1 (de) | 2004-02-04 | 2009-08-15 | Neurosearch As | Dimere azacyclische verbindungen und deren verwendung |
WO2006033795A2 (en) | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
KR101328306B1 (ko) * | 2005-09-21 | 2013-11-11 | 디코드 제네틱스 이에이치에프 | 염증 치료를 위한 lta4h의 바이아릴 치환된헤테로사이클 억제제 |
CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
DK1976828T3 (en) * | 2005-12-29 | 2017-03-06 | Celtaxsys Inc | DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE |
EP2295432A1 (en) | 2006-02-10 | 2011-03-16 | TransTech Pharma Inc. | Process for the preparation of aminobenzimidazole derivatives |
WO2008016131A1 (fr) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
RU2009112495A (ru) | 2006-10-19 | 2010-11-27 | Ф. Хоффманн-Ля Рош Аг (Ch) | Аминометил-2-имидазолы со сродством к рецепторам, ассоциированным со следовыми аминами |
ES2620818T3 (es) | 2006-12-14 | 2017-06-29 | Janssen Pharmaceutica N.V. | Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida |
FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
JP5431316B2 (ja) | 2007-07-02 | 2014-03-05 | エフ.ホフマン−ラ ロシュ アーゲー | Ccr2受容体アンタゴニストとしてのイミダゾール誘導体 |
AU2008334444B2 (en) | 2007-12-12 | 2011-12-15 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors |
US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
MX2012006484A (es) | 2009-12-07 | 2012-08-01 | Targacept Inc | 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina. |
JP5889895B2 (ja) | 2010-07-29 | 2016-03-22 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Ampk活性化複素環化合物およびその使用方法 |
SG193424A1 (en) | 2011-03-15 | 2013-10-30 | Rib X Pharmaceuticals Inc | Antimicrobial agents |
JP2014515370A (ja) | 2011-05-23 | 2014-06-30 | ヤンセン ファーマシューティカ エヌ.ベー. | グルカゴン受容体拮抗薬として有用なピコリンアミド−プロパン酸誘導体 |
-
2006
- 2006-12-22 DK DK06848156.3T patent/DK1976828T3/en active
- 2006-12-22 EP EP16205498.5A patent/EP3205644A1/en not_active Withdrawn
- 2006-12-22 US US11/644,244 patent/US7737145B2/en active Active
- 2006-12-22 ES ES06848156.3T patent/ES2614090T3/es active Active
- 2006-12-22 PL PL06848156T patent/PL1976828T3/pl unknown
- 2006-12-22 SI SI200632152A patent/SI1976828T1/sl unknown
- 2006-12-22 TW TW095148673A patent/TW200730474A/zh unknown
- 2006-12-22 PT PT68481563T patent/PT1976828T/pt unknown
- 2006-12-22 HU HUE06848156A patent/HUE031972T2/hu unknown
- 2006-12-22 LT LTEP06848156.3T patent/LT1976828T/lt unknown
- 2006-12-22 EP EP06848156.3A patent/EP1976828B1/en active Active
- 2006-12-22 WO PCT/US2006/049273 patent/WO2007079078A1/en active Application Filing
- 2006-12-27 AR ARP060105806A patent/AR058404A1/es unknown
- 2006-12-27 PE PE2006001705A patent/PE20071176A1/es not_active Application Discontinuation
- 2006-12-27 UY UY30070A patent/UY30070A1/es not_active Application Discontinuation
-
2010
- 2010-04-30 US US12/771,659 patent/US8569303B2/en active Active
-
2012
- 2012-10-18 US US13/654,669 patent/US20130123243A1/en not_active Abandoned
-
2014
- 2014-06-24 US US14/313,672 patent/US9315509B2/en not_active Expired - Fee Related
-
2016
- 2016-03-14 US US15/069,484 patent/US20160272649A1/en not_active Abandoned
-
2017
- 2017-03-20 CY CY20171100343T patent/CY1118837T1/el unknown
-
2018
- 2018-02-08 US US15/891,585 patent/US20180230159A1/en not_active Abandoned
-
2020
- 2020-01-09 US US16/738,190 patent/US11267819B2/en active Active
-
2022
- 2022-09-14 US US17/944,782 patent/US20230250104A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180230159A1 (en) | 2018-08-16 |
US9315509B2 (en) | 2016-04-19 |
WO2007079078A1 (en) | 2007-07-12 |
EP1976828B1 (en) | 2016-12-21 |
PT1976828T (pt) | 2017-03-10 |
SI1976828T1 (sl) | 2017-07-31 |
US20070155726A1 (en) | 2007-07-05 |
LT1976828T (lt) | 2017-04-25 |
AR058404A1 (es) | 2008-01-30 |
EP1976828A1 (en) | 2008-10-08 |
PE20071176A1 (es) | 2008-02-08 |
TW200730474A (en) | 2007-08-16 |
US20100210630A1 (en) | 2010-08-19 |
US20200308181A1 (en) | 2020-10-01 |
US20130123243A1 (en) | 2013-05-16 |
US20160272649A1 (en) | 2016-09-22 |
CY1118837T1 (el) | 2018-01-10 |
US8569303B2 (en) | 2013-10-29 |
ES2614090T3 (es) | 2017-05-29 |
UY30070A1 (es) | 2007-07-31 |
DK1976828T3 (en) | 2017-03-06 |
US20150080382A1 (en) | 2015-03-19 |
EP3205644A1 (en) | 2017-08-16 |
US11267819B2 (en) | 2022-03-08 |
US20230250104A1 (en) | 2023-08-10 |
US7737145B2 (en) | 2010-06-15 |
PL1976828T3 (pl) | 2017-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11267819B2 (en) | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | |
AU2014239585B2 (en) | Inhibitors of leukotriene A4 hydrolase | |
US10399986B2 (en) | Inhibitors of leukotriene A4 hydrolase | |
US10501455B2 (en) | Inhibitors of leukotriene A4 hydrolase | |
US20070155727A1 (en) | Amide inhibitors of leukotriene A4 hydrolase | |
KR20190088551A (ko) | 루코트리엔 a4 하이드롤라제의 저해제 |